Thomas Joseph M, Li Tianxia, Yang Wei, Xue Fengtian, Fishman Paul S, Smith Wanli W
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy Baltimore, MD, USA.
Department of Neurology, University of Maryland School of MedicineBaltimore, MD, USA; Neurology Service, VA Maryland Healthcare SystemBaltimore, MD, USA.
Front Aging Neurosci. 2017 Jan 10;8:337. doi: 10.3389/fnagi.2016.00337. eCollection 2016.
Leucine-rich repeat kinase 2 is a large protein with implications in genetic and sporadic causes of Parkinson's disease. The physiological functions of LRRK2 are largely unknown. In this report, we investigated whether LRRK2 alters neural transport using live-cell imaging techniques and human neuroblastoma SH-SY5Y cells. Our results demonstrated that expression of the PD-linked mutant, LRRK2-R1441C, induced mitochondrial, and lysosomal transport defects in neurites of SH-SY5Y cells. Most importantly, recently identified GTP-binding inhibitors, 68 and FX2149, can reduce LRRK2 GTP-binding activity and attenuates R1441C-induced mitochondrial and lysosomal transport impairments. These results provide direct evidence and an early mechanism for neurite injury underlying LRRK2-induced neurodegeneration. This is the first report to show that LRRK2 GTP-binding activity plays a critical role during neurite transport, suggesting inhibition of LRRK2 GTP-binding could be a potential novel strategy for PD intervention.
富含亮氨酸重复激酶2是一种大型蛋白质,与帕金森病的遗传和散发性病因有关。LRRK2的生理功能在很大程度上尚不清楚。在本报告中,我们使用活细胞成像技术和人神经母细胞瘤SH-SY5Y细胞研究了LRRK2是否会改变神经运输。我们的结果表明,与帕金森病相关的突变体LRRK2-R1441C的表达在SH-SY5Y细胞的神经突中诱导了线粒体和溶酶体运输缺陷。最重要的是,最近鉴定出的GTP结合抑制剂68和FX2149可以降低LRRK2的GTP结合活性,并减轻R1441C诱导的线粒体和溶酶体运输损伤。这些结果为LRRK2诱导的神经退行性变潜在的神经突损伤提供了直接证据和早期机制。这是第一份表明LRRK2 GTP结合活性在神经突运输过程中起关键作用的报告,提示抑制LRRK2 GTP结合可能是帕金森病干预的一种潜在新策略。